LinkedIn
Specialty
Course Type
Search
Log In
Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In
Menu

Advances in Gene Therapies for Retinal Disorders: Individualized Management of Patients

By: Allen C. Ho, MD, FACS; Robert Avery, MD; Pravin U. Dugel, MD; Jeffrey S. Heier, MD

Begin Course
Webinar Credits: 1.25

Introduction and Overview: Where We’ve Come in Gene Therapy - Presented By Allen C. Ho, MD
Ocular Gene Therapy Delivery - Presented By Robert Avery, MD
Gene Therapy for Wet AMD: Current Clinical Trials - Presented By Jeffrey S. Heier, MD
Changing Retinal Landscape and Implications for Future Therapies - Presented By Pravin U. Dugel, MD
Case Discussion
Closing Comments and CME Posttest - Presented By Allen C. Ho, MD

Expiration Date: Saturday, October 31, 2020
Release Date: October 2019

Learning Objectives

  • Describe gene therapy and how it may be used in treating retinal disorders.
  • Distinguish between gene inhibition, gene augmentation, and gene editing.
  • Explain which retinal disorders are likely to benefit from gene therapy.
  • Differentiate the various gene therapy delivery methods and the differences among them.

Accreditation and Designation Statement

ACCREDITATION STATEMENT
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

Allen C. Ho, MD 

Wills Eye Hospital

Pravin U. Dugel, MD

Retinal Consultants of Arizona

Robert Avery, MD

California Retina Consultants

Jeffrey S. Heier, MD

Ophthalmic Consultants of Boston

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
Robert Avery, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Amgen, Apellis, Bausch + Lomb, Clearside, Eyepoint, Genentech, Helio, lridex, Notal, Novartis, Ocular Theraputix, Regeneron, Replenish, and Santen. Grant Research: Genentech. Shareholder: Alcon, Novartis, Regeneron, and Replenish.

Pravin U. Dugel, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board Member: Abbott/AMO, Acucela, Aerie Pharmaceuticals, Aerpio, Alcon, Alimera Sciences, Allergan, Amgen, Annidis, ArticDX, Avalanche, Bausch + Lomb, Boehringer lngelheim, ByeOnics, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Clearside Biomedical, CDR-Life Inc., Digisight, Dose Medical, Genentech, Graybug Vision, lrenix, Kodiak Sciences, Lutronic, Lux Bioscience, Macusight, NeoVista, Neurotech, Novartis, Oculis, Ophthotech, Omeros, Opthea, Optovue, ORA, Orbis International, Panoptica, Pentavision, pSivida Corporation, QLT, Inc., Regeneron, Roche, Santen, SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth, Biotherapeutics, Thrombogenetics, Topcon, and TrueVision. Stock/Shareholder: Aerpio, Alimera, Annidis, ArctixDx, Clearside Biomedical, Digisight, lrenix, Ophthotech and PanOptic.

Jeffrey S. Heier, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: 4DMT, Aerie, Aerpio, AKROS, Alkahest, Apellis, Array, Asclepix, Bayer, Biomarin, Beaver Visitec International., Daiichi, Eloxx, Galecto, Galimedix, Genentech, Generation Bio, Helie, Interface, Irenixx, Janssen, Kala, Kanghong, Kodiak, Notal Vision, Novartis, Omeicos, Orbit Bioemedical, Regeneron, RegenxBio, Retrotope, Scifluor, Shire, Stealth BioTherapeutics, Thrombogenics, Voyant, and Carl Zeiss Meditec. Grant Research: Aerpio, Apellis, Clearside, Daiichi, Foreseehome, Genentech, Genzyme, Hemera, Janssen, Kalvista, Kanghong, Novartis, Ocudyne, Ophthotech, Optos, Optovue, Regeneron, RegenxBio, and Thrombogenics. Shareholder: Adverum, Aldeyra, Allegro, Digital Surgery Systems, Ocular Therapeutics, and Jcyte.
Allen C. Ho, MD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerpio, Aerie, Alcon, Allergan, Asclepix, BeaverEndoOptiks, BioTime, Chengdu Kang Hong, Eloxx, Everads, Genentech, Janssen, Notal, Ocugenix, ONL, Optovue, Orbit Biomedical, PanOptica, PRN, ProQR, Regeneron, RegenxBio, Sanofi, and Second Sight. Grant Support: Aerie, AGTC, Alcon, Allergan, Apellis, Chengdu Kang Hong, Genentech, Janssen, NEI/NIH, ProQR, Regeneron, RegenxBio , Sanofi, and Second Sight. Stock/Shareholder: Covalent, ONL, PanOptica, PRN, and Visionary Ventures.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.

Disclaimer

Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or REGENXBIO.

Pretest

  • 1 Not at all confident2 Not very confident3 Neutral4 Confident5 Very confident

Video Resources

Advances in Gene Therapies for Retinal Disorders: Individualized Management of Patients

By: Allen Ho, MD; Pravin Dugel, MD; Bob Avery, MD; Jeff Heier, MD

Next

Test

Instructions

Step 1 of 2

50%
  • 1 Not at all confident2 Not very confident3 Neutral4 Confident5 Very confident
  • AgreeNeutralDisagree
    Describe gene therapy and how it may be used in treating retinal disorders.
    Distinguish between gene inhibition, gene augmentation, and gene editing.
    Explain which retinal disorders are likely to benefit from gene therapy.
    Differentiate the various gene therapy delivery methods and the differences among them.
Back